To assess long-term outcomes of children with symptomatic congenital cytomegalovirus (CMV) disease detected at birth.
We used Cox regression to assess risk factors for intellectual disability (intelligence quotient <70), sensorineural hearing loss (SNHL; hearing level ⩾25 dB in any audiometric frequency) and vision impairment (best corrected visual acuity >20 or based on ophthalmologist report).
Among 76 case-patients followed through median age of 13 (range: 0–27) years, 56 (74%) had SNHL, 31 (43%, n=72) had intellectual disability and 18 (27%, n=66) had vision impairment; 28 (43%, n=65) had intellectual disability and SNHL with/without vision impairment. Microcephaly was significantly associated with each of the three outcomes. Tissue destruction and dysplastic growth on head computed tomography scan at birth was significantly associated with intellectual disability and SNHL.
Infants with symptomatic congenital CMV disease may develop moderate to severe impairments that were associated with presence of microcephaly and brain abnormalities.
Your institute does not have access to this article
Open Access articles citing this article.
A framework for assessing the lifetime economic burden of congenital cytomegalovirus in the United States
Cost Effectiveness and Resource Allocation Open Access 03 October 2019
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Dollard SC, Grosse SD, Ross DS . New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007; 17 (5): 355–363.
Boppana SB, Ross SA, Shimamura M, Palmer AL, Ahmed A, Michaels MG et al. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. N Engl J Med 2011; 364 (22): 2111–2118.
Boppana SB, Ross SA, Novak Z, Shimamura M, Tolan RW Jr, Palmer AL et al. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA 2010; 303 (14): 1375–1382.
Ahlfors K, Ivarsson SA, Harris S . Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature. Scand J Infect Dis 1999; 31 (5): 443–457.
Boppana SB, Fowler KB, Britt WJ, Stagno S, Pass RF . Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 1999; 104 (1 Pt 1): 55–60.
Melish ME, Hanshaw JB . Congenital cytomegalovirus infection. Developmental progress of infants detected by routine screening. Am J Dis Child 1973; 126 (2): 190–194.
Numazaki K, Fujikawa T . Chronological changes of incidence and prognosis of children with asymptomatic congenital cytomegalovirus infection in Sapporo, Japan. BMC Infect Dis 2004; 4: 22.
Peckham CS, Chin KS, Coleman JC, Henderson K, Hurley R, Preece PM . Cytomegalovirus infection in pregnancy: preliminary findings from a prospective study. Lancet 1983; 1 (8338): 1352–1355.
Saigal S, Lunyk O, Larke RP, Chernesky MA . The outcome in children with congenital cytomegalovirus infection. A longitudinal follow-up study. Am J Dis Child 1982; 136 (10): 896–901.
Starr JG, Bart RD Jr, Gold E . Inapparent congenital cytomegalovirus infection. Clinical and epidemiologic characteristics in early infancy. N Engl J Med 1970; 282 (19): 1075–1078.
Yow MD, Williamson DW, Leeds LJ, Thompson P, Woodward RM, Walmus BF et al. Epidemiologic characteristics of cytomegalovirus infection in mothers and their infants. Am J Obstet Gynecol 1988; 158 (5): 1189–1195.
Koyano S, Inoue N, Oka A, Moriuchi H, Asano K, Ito Y et al. Screening for congenital cytomegalovirus infection using newborn urine samples collected on filter paper: feasibility and outcomes from a multicentre study. BMJ Open 2011; 1 (1): e000118.
Kimberlin DW, Jester PM, Sanchez PJ, Ahmed A, Arav-Boger R, Michaels MG et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 2015; 372 (10): 933–943.
Kimberlin DW, Lin CY, Sanchez PJ, Demmler GJ, Dankner W, Shelton M et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003; 143 (1): 16–25.
Lanzieri TM, Bialek SR, Bennett MV, Gould JB . Cytomegalovirus infection among infants in California neonatal intensive care units, 2005-2010. J Perinat Med 2014; 42 (3): 393–399.
Cannon MJ, Griffiths PD, Aston V, Rawlinson WD . Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit? Rev Med Virol 2014; 24 (5): 291–307.
Lanzieri TM, Dollard SC, Bialek SR, Grosse SD . Systematic review of the birth prevalence of congenital cytomegalovirus infection in developing countries. Int J Infect Dis 2014; 22: 44–48.
Williamson WD, Demmler GJ, Percy AK, Catlin FI . Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatrics 1992; 90 (6): 862–866.
Lanzieri TM, Chung W, Flores M, Blum P, Caviness AC, Bialek SR et al. Hearing loss in children with asymptomatic congenital cytomegalovirus infection. Pediatrics 2017 (e-pub ahead of print 16 February 2017;doi:10.1542/peds.2016-2610).
Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS . New intrauterine growth curves based on United States data. Pediatrics 2010; 125 (2): e214–e224.
Bayley N . Bayley Scales of Infant Development. Psychological Corporation: 3San Antonio, TX, 1969.
McCarthy D . McCarthy Scale of Children's Abilities. Psychological Corp: New York, 1972.
Wechsler D . Wechsler Intelligence Scale for Children, 3rd edn. The Psychological Corporation: San Antonio, TX, 1991.
Wechsler D . Wechsler Abbreviated Scale of Intelligence. The Psychological Corporation: San Antonio, TX, USA, 1999.
Kaufman AS, Kaufman NL . Kaufman Assessment Battery for Children. American Guidance Service: Circle Pines, MN, 1983.
Roid G, Miller L . Leiter International Performance Scale-Revised: Examiner’s Manual. Stoelting: Wood Dale, IL, 1997.
Thorndike RHE, Sattler J . The Stanford-Binet Intelligence Scale Fourth Edition Guide for Administering And Scoring. Riverside Pub: Chicago, IL, 1986, p192.
Sparrow SS, Balla DA, Cicchetti DV . Vineland Adaptive Behavior Scales—Interview Edition Survey Form. American Guidance Service: Circle Pines, MN, 1984.
Sampath V, Bowen J, Gibson F . Risk factors for adverse neurodevelopment in extremely low birth weight infants with normal neonatal cranial ultrasound. J Perinatol 2005; 25 (3): 210–215.
National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention. Metropolitan Atlanta Developmental Disabilities Surveillance Program (MADDSP) Case Definitions. [cited 30 September 2016.]Available fromhttp://www.cdc.gov/ncbddd/developmentaldisabilities/casedefinitions.html#vision.
King G, Zeng L . Logistic regression in rare events data. Pol Anal 2001; 9: 137–163.
Dreher AM, Arora N, Fowler KB, Novak Z, Britt WJ, Boppana SB et al. Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr 2014; 164 (4): 855–859.
Townsend CL, Forsgren M, Ahlfors K, Ivarsson SA, Tookey PA, Peckham CS . Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. Clin Infect Dis 2013; 56 (9): 1232–1239.
Noyola DE, Demmler GJ, Nelson CT, Griesser C, Williamson WD, Atkins JT et al. Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J Pediatr 2001; 138 (3): 325–331.
Boppana SB, Fowler KB, Vaid Y, Hedlund G, Stagno S, Britt WJ et al. Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics 1997; 99 (3): 409–414.
Alarcon A, Martinez-Biarge M, Cabanas F, Quero J, Garcia-Alix A . A prognostic neonatal neuroimaging scale for symptomatic congenital cytomegalovirus infection. Neonatology 2016; 110 (4): 277–285.
van der Knaap MS, Vermeulen G, Barkhof F, Hart AA, Loeber JG, Weel JF . Pattern of white matter abnormalities at MR imaging: use of polymerase chain reaction testing of Guthrie cards to link pattern with congenital cytomegalovirus infection. Radiology 2004; 230 (2): 529–536.
Lanari M, Capretti MG, Lazzarotto T, Gabrielli L, Rizzollo S, Mostert M et al. Neuroimaging in CMV congenital infected neonates: how and when. Early Hum Dev 2012; 88 (Suppl 2): S3–S5.
Hazin AN, Poretti A, Di Cavalcanti Souza Cruz D, Tenorio M, van der Linden A, Pena LJ et al. Computed Tomographic Findings in Microcephaly Associated with Zika Virus. N Engl J Med 2016; 374 (22): 2193–2195.
Malik V, Bruce IA, Broomfield SJ, Henderson L, Green KM, Ramsden RT . Outcome of cochlear implantation in asymptomatic congenital cytomegalovirus deafened children. Laryngoscope 2011; 121 (8): 1780–1784.
Viccaro M, Filipo R, Bosco E, Nicastri M, Mancini P . Long-term follow-up of implanted children with cytomegalovirus-related deafness. Audiol Neurootol 2012; 17 (6): 395–399.
Ciorba A, Bovo R, Trevisi P, Bianchini C, Arboretti R, Martini A . Rehabilitation and outcome of severe profound deafness in a group of 16 infants affected by congenital cytomegalovirus infection. Eur Arch Otorhinolaryngol 2009; 266 (10): 1539–1546.
Matsui T, Ogawa H, Yamada N, Baba Y, Suzuki Y, Nomoto M et al. Outcome of cochlear implantation in children with congenital cytomegalovirus infection or GJB2 mutation. Acta Otolaryngol 2012; 132 (6): 597–602.
American Academy of Audiology. Cochlear Implants in Children. Cited 23 March 2017. Available from http://www.audiology.org/publications-resources/document-library/cochlear-implants-children.
Ghekiere S, Allegaert K, Cossey V, Van Ranst M, Cassiman C, Casteels I . Ophthalmological findings in congenital cytomegalovirus infection: when to screen, when to treat? J Pediatr Ophthalmol Strabismus 2012; 49 (5): 274–282.
Anderson KS, Amos CS, Boppana S, Pass R . Ocular abnormalities in congenital cytomegalovirus infection. J Am Optom Assoc 1996; 67 (5): 273–278.
Coats DK, Demmler GJ, Paysse EA, Du LT, Libby C . Ophthalmologic findings in children with congenital cytomegalovirus infection. J AAPOS 2000; 4 (2): 110–116.
Gantt S, Dionne F, Kozak FK, Goshen O, Goldfarb DM, Park AH et al. Cost-effectiveness of universal and targeted newborn screening for congenital cytomegalovirus infection. JAMA Pediatr 2016; 170 (12): 1173–1180.
Grosse SD, Ross DS, Dollard SC . Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. J Clin Virol 2008; 41 (2): 57–62.
Fowler KB, McCollister FP, Sabo DL, Shoup AG, Owen KE, Woodruff JL et al. A targeted approach for congenital cytomegalovirus screening within newborn hearing screening. Pediatrics 2017 (e-pub ahead of print 3 January 2017;doi:10.1542/peds.2016-2128).
Townsend CL, Peckham CS, Tookey PA . Surveillance of congenital cytomegalovirus in the UK and Ireland. Arch Dis Child Fetal Neonatal Ed 2011; 96 (6): F398–F403.
Grosse SD, Dollard S, Ross DS, Cannon M . Newborn screening for congenital cytomegalovirus: Options for hospital-based and public health programs. J Clin Virol 2009; 46 (Suppl 4): S32–S36.
Dollard SC, Schleiss MR, Grosse SD . Public health and laboratory considerations regarding newborn screening for congenital cytomegalovirus. J Inherit Metab Dis 2010; 33 (Suppl 2): S249–S254.
We thank all the children who participated in the study, their families and physicians for their lifetime of dedication and support for this study, and Kim Van Naarden Braun for careful review of the manuscript. The study was supported, in part, by the CMV Research Fund Donors at Baylor College of Medicine; the Woman’s Hospital of Texas Research Foundation; the Office of Research Resources and the General Clinical Research Center for Children at Texas Children’s Hospital and Baylor College of Medicine (NIH 5M0I RR00188-33); the Mental Retardation Research Center at Baylor College of Medicine (NIH-CHHD 5 P30 HD24064P); the Research to Prevent Blindness, New York, NY; the Deafness Foundation, Houston, TX; the Vale Ashe Foundation, Houston, TX; the Maddie’s Mission Foundation, Katy, TX; the Naymola Foundation, Beaumont, TX; the American Pediatric Society-Society for Pediatric Research Summer Student Research Program (NIH-CHHD); and the Centers for Disease Control and Prevention (Cooperative Agreement FOA IP 10-006).
The Congenital CMV Longitudinal Study Group through the years has included: Shahzad Ahmed, Hanna Baer, Amit R Bhatt, Peggy Blum and Texas Children's Hospital Audiology, Frank Brown, Francis Catlin, Alison C Caviness, David K Coats, Jane C Edmonds, Marily Flores, Daniel Franklin, Cindy Gandaria, Jewel Greer, Carol Griesser, Mohamed A. Hussein, Isabella Iovino, Allison Istas, Haoxing (Douglas) Jin, Mary K Kelinske, Joseph T Klingen, Antone Laurente, Thomas Littman, Mary Murphy, Jerry Miller, Christopher Nelson, Daniel Noyola, Evelyn A Paysse, Alan Percy, Sara Reis, Ann Reynolds, Judith Rozelle, O’Brien Smith, Paul Steinkuller, Marie Turcich, Sherry Sellers Vinson, Robert G Voigt, Bethann Walmus, Jill Williams, Daniel Williamson, Kimberly G Yen, Martha D Yow and Gail J Demmler-Harrison.
TML conceptualized and conducted analysis contained in this report, interpreted the data, led the writing of the initial manuscript and revised versions and approved the final version; JL conducted analysis contained in this report, interpreted the data, revised the manuscript and approved the final version; WC conceptualized the analysis contained in this report, reviewed and interpreted individual audiological data, revised the manuscript and approved the final version; MF and JAM assisted with data management and quality control for the Longitudinal Congenital CMV Study, revised the manuscript and approved the final version; PB conceptualized and provided audiological follow-up in the Longitudinal Congenital CMV Study, revised the manuscript and approved the final version; ACC was the co-Principal Investigator for the Longitudinal Congenital CMV Study, revised individual clinical, laboratory and head computed tomography data, conducted analysis contained in this report, revised the manuscript and approved the final version; SRB conceptualized the analysis contained in this report, interpreted the data, revised the manuscript and approved the final version; SSV, MRT and RGV conducted the neurodevelopmental evaluations, revised the manuscript and approved the final version; GD-H was the Principal Investigator for the Longitudinal Congenital CMV Study, provided patient follow-up, conceptualized the analysis contained in this report, interpreted the data, revised the manuscript and approved the final version.
Dr Demmler-Harrison’s institution received funding from Merck Sharpe & Dohme Corporation since July 2016 to assist with salary support for further analysis on long-term outcomes of congenital CMV infection not included in this report. The remaining authors declare no conflict of interest.
The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
About this article
Cite this article
Lanzieri, T., Leung, J., Caviness, A. et al. Long-term outcomes of children with symptomatic congenital cytomegalovirus disease. J Perinatol 37, 875–880 (2017). https://doi.org/10.1038/jp.2017.41
Impairment in neurocognitive function following experimental neonatal guinea pig cytomegalovirus infection
Pediatric Research (2021)
A framework for assessing the lifetime economic burden of congenital cytomegalovirus in the United States
Cost Effectiveness and Resource Allocation (2019)